FADD Monoclonal Antibody

Background
Predicted to enable several functions, including caspase binding activity; death effector domain binding activity; and tumor necrosis factor receptor superfamily binding activity. Involved in several processes, including hematopoietic or lymphoid organ development; negative regulation of activation-induced cell death of T cells; and positive regulation of CD8-positive, alpha-beta cytotoxic T cell extravasation. Acts upstream of or within extrinsic apoptotic signaling pathway in absence of ligand; motor neuron apoptotic process; and regulation of programmed cell death. Predicted to be located in several cellular components, including cell body; cytosol; and membrane raft. Predicted to be part of CD95 death-inducing signaling complex and ripoptosome. Predicted to be active in cytoplasm. Is expressed in several structures, including alimentary system; brain; genitourinary system; hemolymphoid system gland; and liver and biliary system. Human ortholog(s) of this gene implicated in leukemia. Orthologous to human FADD (Fas associated via death domain).

Description
FADD Monoclonal Antibody. Unconjugated. Raised in: Rabbit.

Formulation
Buffer: PBS containing 50% glycerol and 0.05% BSA, preserved with proclin300 or sodium azide, pH 7.3.

Specificity
Human, Mouse, Rat

Isotype
IgG

Uniprot ID
Q61160

Purification
Affinity Purified

Immunogen
Recombinant protein (or fragment). Please contact EpigenTek for more information.

Storage
Store at -20°C. Avoid freeze / thaw cycles.

Alternative Names
Mort1/FADD; FADD

Application
WB, IHC-P, ELISA; Recommended dilution: WB, 1:500 - 1:2000; IHC-P, 1:200 - 1:800; ELISA, Recommended starting concentration is 1 µg/mL. Please optimize the concentration based on your specific assay requirements.